is victoza a glp 1 agonist Diabetes patients now have access to first generic GLP-1 medication: ‘More accessible and affordable’ Beware: Same Ingredients, Different FDA

The collective results demonstrate that combined therapy of sCT and liraglutide significantly reduced food intake and body weight compared to vehicle and to a greater degree than the magnitude of food intake and body weight suppression observed after treatment with either mono-therapy alone (Fig

Most side effects of GLP- 1 and GLP- 1/GIP receptor agonists are mild to moderate and resolve over time

doi: 10.1186/s12933-017-0553-3

In the GLP-1 RA vs SGLT-2 inhibitor cohort, there was no difference in the adjusted HR of suicide or suicide attempts between patients treated with GLP-1 RAs compared with patients treated with SGLT-2 inhibitors after 1 year of follow-up (HR 365 0.93 [0.57;1.52]), see Table 2

Although SUMMIT also demonstrated a reduction in the composite endpoint of cardiovascular death or worsening HF events, the magnitude of the improvement, specifically in the KCCQ-CSS observed with higher-dose semaglutide (STEP-HFpEF